Peter Terness

Mannheim, BW 68167, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Correction: Oweira et al. Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepaRG Tumor Cells. J. Clin. Med. 2022, 11, 4794.

Correction: Oweira et al. Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepaRG Tumor Cells. J. Clin. Med. 2022, 11, 4794.

Journal: Journal of clinical medicine
Published: February 09, 2023

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial.

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial.

Journal: BMJ open
Published: November 11, 2022

Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.

Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.

Journal: Frontiers in immunology
Published: November 04, 2022

Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepG2 Tumor Cells.

Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepG2 Tumor Cells.

Journal: Journal of clinical medicine
Published: July 11, 2022

Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients.

Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients.

Journal: Journal of the American Society of Nephrology : JASN
Published: February 24, 2022

Immunosuppressive effect of mitomycin C-treated peripheral mononuclear blood cells (MICs) in vascularised composite allotransplantation

Immunosuppressive effect of mitomycin C-treated peripheral mononuclear blood cells (MICs) in vascularised composite allotransplantation

Journal: Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V...
Published: January 07, 2021

Comparison of early pregnancy serum concentration of neopterin, neopterin/creatinine ratio, C-reactive protein, and chitotriosidase, in pregnant women with birth at term and spontaneous preterm birth.

Comparison of early pregnancy serum concentration of neopterin, neopterin/creatinine ratio, C-reactive protein, and chitotriosidase, in pregnant women with birth at term and spontaneous preterm birth.

Journal: Experimental and therapeutic medicine
Published: April 13, 2020

Phase I trial of donor-derived modified immune cell infusion in kidney transplantation.

Phase I trial of donor-derived modified immune cell infusion in kidney transplantation.

Journal: The Journal of clinical investigation
Published: September 23, 2019

Association of pre- and early post-transplant serum amino acids and metabolites of amino acids and liver transplant outcome.

Association of pre- and early post-transplant serum amino acids and metabolites of amino acids and liver transplant outcome.

Journal: Transplant immunology
Published: November 24, 2016

The combination of mitomycin-induced blood cells with a temporary treatment of ciclosporin A prolongs allograft survival in vascularized composite allotransplantation.

The combination of mitomycin-induced blood cells with a temporary treatment of ciclosporin A prolongs allograft survival in vascularized composite allotransplantation.

Journal: Langenbeck's archives of surgery
Published: September 23, 2016

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation.

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation.

Journal: Pediatric nephrology (Berlin, Germany)
Published: July 29, 2016

Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.

Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.

Journal: Journal of translational medicine
Published: June 02, 2015
Showing 1-12 of 22

Last Updated: 09/26/2026